At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed ovarian epithelial cancer of one of the specified cell types (serous, Brenner, mucinous, endometrioid, clear cell, undifferentiated, transitional cell, mixed epithelial, or NOS adenocarcinoma)
- ✓Stage Ia or Ib grade 3 or clear cell, OR Stage Ic or II any grade/histology
- ✓Complete surgical staging performed
- ✓WBC at least 3,000/mm³
- ✕Tumors of low malignant potential (borderline tumors)
- ✕Other invasive malignancies within the past 5 years except nonmelanoma skin cancer
- ✕Major systemic medical illness expected to affect survival
- ✕Body surface area greater than 2.0 m²
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma
In Brief
A Phase 3 clinical trial evaluating carboplatin and paclitaxel for Ovarian Cancer. Completed, enrolled 571 participants across 151 sites in 2 countries.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effective than carboplatin and paclitaxel alone for early-stage ovarian cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel alone too see how well they work compared to carboplatin and paclitaxel together with continued low-dose paclitaxel in treating patients with early-stage ovarian cancer.